Illawarra Health Medical Research Institute, University of Wollongong, New South Wales, Australia.
Acta Psychiatr Scand. 2012 Jan;125(1):39-44. doi: 10.1111/j.1600-0447.2011.01776.x. Epub 2011 Oct 24.
Approximately 30% of individuals diagnosed with schizophrenia suffer from treatment-resistant or refractory schizophrenia. The gold standard for treatment of refractory schizophrenia is clozapine. However, a significant number of patients cease clozapine therapy; therefore this study explores patient's motives for cessation.
The motives for cessation and duration of clozapine treatment from a retrospective database of 151 patients with schizophrenia or schizo-affective disorder who had ceased clozapine once or more were reviewed, with the motives for cessation coded. The general motives for cessation were non-compliance, own decision, medical, poor response and other. In addition, the medical reasons for cessation were further codified: cardiac complications, neutropenia, fevers, other side effects and pregnancy.
The majority of patients ceased clozapine owing to non-compliance with medical protocols or citing their own decision. Approximately half ceased after a period of 6 months or less. Seventeen per cent of patients ceased owing to medical reasons, with the largest proportions discontinuing treatment because of other side effects or neutropenia.
Future research should seek to further investigate why patients decide to be non-compliant and formulate their own decision to cease treatment, as this will facilitate strategies to promote adherence amongst these two groups that are potentially the most amenable to change.
约 30%的精神分裂症患者患有治疗抵抗或难治性精神分裂症。难治性精神分裂症的金标准治疗方法是氯氮平。然而,相当数量的患者停止了氯氮平治疗;因此,本研究探讨了患者停药的动机。
回顾性分析了 151 例曾停止氯氮平治疗一次或多次的精神分裂症或分裂情感障碍患者的数据库,对停药的动机进行了编码。停药的一般动机包括不遵医嘱、自行决定、医疗、疗效不佳和其他原因。此外,还进一步对停药的医疗原因进行了编码:心脏并发症、中性粒细胞减少症、发热、其他副作用和妊娠。
大多数患者因不遵守医疗方案或自行决定而停止服用氯氮平。大约一半的患者在 6 个月或更短的时间内停止治疗。17%的患者因医疗原因停止治疗,其中因其他副作用或中性粒细胞减少症而停止治疗的比例最大。
未来的研究应进一步探讨为什么患者决定不遵医嘱并自行决定停止治疗,因为这将有助于制定策略,促进这两组患者的依从性,这两组患者最有可能改变。